Sanctuary Advisors LLC Purchases 24,871 Shares of CVS Health Corporation $CVS

Sanctuary Advisors LLC boosted its position in CVS Health Corporation (NYSE:CVS) by 14.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 199,236 shares of the pharmacy operator’s stock after purchasing an additional 24,871 shares during the period. Sanctuary Advisors LLC’s holdings in CVS Health were worth $14,309,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of CVS. Swiss RE Ltd. bought a new stake in shares of CVS Health during the 4th quarter worth approximately $26,000. Sankala Group LLC purchased a new stake in CVS Health in the fourth quarter worth $28,000. Caitong International Asset Management Co. Ltd lifted its position in shares of CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares during the last quarter. Mcguire Capital Advisors Inc. bought a new stake in shares of CVS Health during the fourth quarter worth $28,000. Finally, Ares Financial Consulting LLC purchased a new stake in shares of CVS Health during the fourth quarter valued at $29,000. Institutional investors own 80.66% of the company’s stock.

More CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is benefiting from a sector-wide lift after UnitedHealth delivered a large earnings beat and raised guidance, which helped improve sentiment across managed-care stocks including CVS. UNH Stock Flashes Buy Signal On Massive Earnings Beat
• Positive Sentiment: Truist reportedly reiterated a bullish stance with a new $118 price target, reinforcing the view that CVS still has room to run after recently hitting fresh highs. CVS Health Given New $118.00 Price Target at Truist Financial
• Positive Sentiment: CVS also continues to draw favorable analyst attention, with reports highlighting optimistic Wall Street recommendations and broader confidence in the stock’s fundamentals. Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: Aetna’s provider survey showed improved payer trust and interest in digital tools, which is constructive for CVS Health’s Aetna segment but not likely a near-term stock mover. Aetna provider survey reveals increased payer trust and tangible benefits of digital tools to improve patient outcomes
• Negative Sentiment: Regulatory scrutiny remains a key overhang after reports that CVS Caremark reached a settlement with the FTC over rebate practices, pharmacy access, and transparency, which could pressure margins or invite more oversight. FTC Says CVS Caremark Settlement Could Save Consumers Upto $13 Billion
• Negative Sentiment: Some commentary also suggests CVS may be trading at a demanding valuation after its recent run, which could limit upside if earnings growth does not keep pace. The Real Price of Admission for CVS Health Stock

CVS Health Trading Up 0.6%

NYSE CVS opened at $106.51 on Friday. The company’s 50-day simple moving average is $98.64 and its two-hundred day simple moving average is $84.98. CVS Health Corporation has a one year low of $58.50 and a one year high of $108.67. The company has a market capitalization of $135.90 billion, a price-to-earnings ratio of 46.92, a price-to-earnings-growth ratio of 1.03 and a beta of 0.61. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities analysts forecast that CVS Health Corporation will post 7.46 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be given a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, July 23rd. CVS Health’s payout ratio is presently 117.18%.

Insiders Place Their Bets

In related news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Larry Robbins sold 370,462 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last 90 days. 0.85% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on CVS shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of CVS Health in a research note on Friday, May 8th. UBS Group upped their target price on shares of CVS Health from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. Royal Bank Of Canada raised their target price on shares of CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, July 9th. DA Davidson boosted their price target on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Wall Street Zen downgraded CVS Health from a “buy” rating to a “hold” rating in a report on Wednesday. Twenty-one equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $105.38.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.